Indicator #3 The cost of Financialization: More Spent on Shareholders than R&D (FIGURE 3) Ratio of Spending on R&D vs Shareholder Enrichment for Leading Pharmaceutical Companies 2020-2024 The figure shows the ratio of total spending on R&D versus shareholder enrichment (stock buybacks plus shareholder dividends) for 15 peer companies during the five year period from 2020-2024
Other findings included: Gallbladder issues (especially with rapid weight loss) Pancreatitis (rare, with unclear causality) Thyroid C-cell hyperplasia (in animals, not seen in humans) Lean mass lossup to 40% of weight lost may be muscle in older adults None of these derailed regulatory approvals
Moving around can make it worse
For the side effect phenotypes, we defined separate casecontrol phenotypes for each side effect recorded in the survey, contrasting those who self-rated their side effects as moderate or severe (cases) to those who self-rated their side effects as mild or non-existent (controls)
Alongside its effects on GLP-1, it also mimics the actions of another hormone called GIP (gastric inhibitory polypeptide) that reduces blood sugar levels
Diabetes Peptide & Obesity Peptide Catalog Custom Diabetes & Obesity Peptide Synthesis JPT offers custom peptide synthesis for researchers in the fields of diabetes and obesity
.webp)
